Clinical trials: surrogate endpoints or hard endpoints?

Area of Science:

• Cardiovascular Medicine
• Preventive Cardiology
• Medical Imaging

Background:

• Lifetime risk of myocardial infarction (MI) is significant, with a 50-year-old man having a 50% risk and a 50-year-old woman a 35% risk.
• The extent of atherosclerosis is the primary determinant of MI risk.
• Substantial reduction in coronary artery disease (CAD) lifetime risk necessitates primary prevention of atherosclerosis.

Purpose of the Study:

• To highlight the importance of noninvasive methods for measuring subclinical atherosclerosis.
• To emphasize the role of subclinical disease in improving patient-specific preventive strategies.
• To underscore the potential for new drug development and understanding of atherosclerosis.

Main Methods:

• Utilizing noninvasive imaging techniques to assess subclinical atherosclerosis.
• Monitoring the progression of subclinical atherosclerosis.
• Analyzing plaque characteristics to understand atherosclerosis development.

Main Results:

• Subclinical atherosclerosis measurement offers a unique opportunity for personalized preventive strategies.
• Pharmacologic and nonpharmacologic therapies can be optimized based on subclinical disease assessment.
• Subclinical disease serves as a surrogate marker for atherosclerosis, aiding in research.

Conclusions:

• Primary prevention of atherosclerosis is crucial for reducing lifetime CAD risk.
• Noninvasive assessment of subclinical atherosclerosis enhances understanding of risk factors, lipoprotein metabolism, and genetic-lifestyle interactions.
• Further research into subclinical disease and plaque characteristics is vital for advancing cardiovascular medicine.